These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 20615140)
1. Effects of silencing RET/PTC1 junction oncogene in human papillary thyroid carcinoma cells. Gilbert-Sirieix M; Ripoche H; Malvy C; Massaad-Massade L Thyroid; 2010 Oct; 20(10):1053-65. PubMed ID: 20615140 [TBL] [Abstract][Full Text] [Related]
2. Effects of silencing the RET/PTC1 oncogene in papillary thyroid carcinoma by siRNA-squalene nanoparticles with and without fusogenic companion GALA-cholesterol. Ali HM; Maksimenko A; Urbinati G; Chapuis H; Raouane M; Desmaële D; Yasuhiro H; Harashima H; Couvreur P; Massaad-Massade L Thyroid; 2014 Feb; 24(2):327-38. PubMed ID: 23885719 [TBL] [Abstract][Full Text] [Related]
3. Effects of siRNA on RET/PTC3 junction oncogene in papillary thyroid carcinoma: from molecular and cellular studies to preclinical investigations. Ali HM; Urbinati G; Chapuis H; Desmaele D; Bertrand JR; Couvreur P; Massaad-Massade L PLoS One; 2014; 9(4):e95964. PubMed ID: 24759995 [TBL] [Abstract][Full Text] [Related]
4. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors. Henderson YC; Fredrick MJ; Clayman GL Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622 [TBL] [Abstract][Full Text] [Related]
5. Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese. Liu RT; Chou FF; Wang CH; Lin CL; Chao FP; Chung JC; Huang CC; Wang PW; Cheng JT Thyroid; 2005 Apr; 15(4):326-35. PubMed ID: 15876154 [TBL] [Abstract][Full Text] [Related]
6. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. Rhoden KJ; Unger K; Salvatore G; Yilmaz Y; Vovk V; Chiappetta G; Qumsiyeh MB; Rothstein JL; Fusco A; Santoro M; Zitzelsberger H; Tallini G J Clin Endocrinol Metab; 2006 Jun; 91(6):2414-23. PubMed ID: 16595592 [TBL] [Abstract][Full Text] [Related]
7. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications. Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156 [TBL] [Abstract][Full Text] [Related]
8. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer. Ruan M; Liu M; Dong Q; Chen L J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669 [TBL] [Abstract][Full Text] [Related]
9. Role of H2O2 in RET/PTC1 chromosomal rearrangement produced by ionizing radiation in human thyroid cells. Ameziane-El-Hassani R; Boufraqech M; Lagente-Chevallier O; Weyemi U; Talbot M; Métivier D; Courtin F; Bidart JM; El Mzibri M; Schlumberger M; Dupuy C Cancer Res; 2010 May; 70(10):4123-32. PubMed ID: 20424115 [TBL] [Abstract][Full Text] [Related]
10. Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. Raouane M; Desmaele D; Gilbert-Sirieix M; Gueutin C; Zouhiri F; Bourgaux C; Lepeltier E; Gref R; Ben Salah R; Clayman G; Massaad-Massade L; Couvreur P J Med Chem; 2011 Jun; 54(12):4067-76. PubMed ID: 21561161 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. Zhu Z; Ciampi R; Nikiforova MN; Gandhi M; Nikiforov YE J Clin Endocrinol Metab; 2006 Sep; 91(9):3603-10. PubMed ID: 16772343 [TBL] [Abstract][Full Text] [Related]
12. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements. Mechler C; Bounacer A; Suarez H; Saint Frison M; Magois C; Aillet G; Gaulier A Br J Cancer; 2001 Dec; 85(12):1831-7. PubMed ID: 11747322 [TBL] [Abstract][Full Text] [Related]
13. Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma. Rhoden KJ; Johnson C; Brandao G; Howe JG; Smith BR; Tallini G Lab Invest; 2004 Dec; 84(12):1557-70. PubMed ID: 15502856 [TBL] [Abstract][Full Text] [Related]
15. The roles of phosphotyrosines-294, -404, and -451 in RET/PTC1-induced thyroid tumor formation. Buckwalter TL; Venkateswaran A; Lavender M; La Perle KM; Cho JY; Robinson ML; Jhiang SM Oncogene; 2002 Nov; 21(53):8166-72. PubMed ID: 12444552 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of the growth of papillary thyroid carcinoma cells by CI-1040. Henderson YC; Ahn SH; Clayman GL Arch Otolaryngol Head Neck Surg; 2009 Apr; 135(4):347-54. PubMed ID: 19380355 [TBL] [Abstract][Full Text] [Related]
17. RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase. De Falco V; Castellone MD; De Vita G; Cirafici AM; Hershman JM; Guerrero C; Fusco A; Melillo RM; Santoro M Cancer Res; 2007 Jan; 67(1):381-90. PubMed ID: 17210721 [TBL] [Abstract][Full Text] [Related]
18. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036 [TBL] [Abstract][Full Text] [Related]
19. RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho. Barone MV; Sepe L; Melillo RM; Mineo A; Santelli G; Monaco C; Castellone MD; Tramontano D; Fusco A; Santoro M Oncogene; 2001 Oct; 20(48):6973-82. PubMed ID: 11704822 [TBL] [Abstract][Full Text] [Related]